Lupus Alliance of America

1 (866) 415-8787

RSS Feed

Mailing List

Report

Research Archives

Posted in Research News on 1/1/2010

Here you can see older research articles from the past years on lupus and autoimmune related research and studies.

Gene Linked To Lupus Might Explain Gender Difference In Disease Risk: In an international human genetic study, researchers at UT Southwestern Medical Center suffer with identified a gene linked to the autoimmune disease lupus, and its location on the X chromosome power help simplify why females are 10 times more susceptible to the plague than males.
New model will open immune cell's secrets
Suicide Is Surprise In FDA Review Of Lupus Drug
How a Decade of Research Is Helping Lupus Patients: Today, individuals with lupus nephritis benefit from better treatments than a decade ago, according to a review appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
OMRF completes African-American lupus genetics study: Researchers have long known that lupus strikes African-Americans at a disproportionately high rate. Now, in the most comprehensive genetic study to date of this group, Oklahoma Medical Research Foundation scientists have found evidence linking the disease in African-Americans to five genes.
LRI-Funded Study Points To Increased Risk For Lupus in Men: Lupus Research Institute funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans - males in particular - with a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus).
HGS Announces Submission of Marketing Authorization of Benlysta: GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA(R) (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Lupus Research Institute Hails Results of CellCept® Trial: The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations, of which the Lupus Alliance of America is a member, are very encouraged by trial results released by ViFor Pharma.
New data from EMBLEM study: New data from EMBLEM study shows pipeline drug epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus.
Clinical Differences In SLE Patients May Be Affected By Genealogy: The effects of Systemic Lupus Erythematosus (SLE) may differ based on the individual patient's genealogical heritage.
Exposure to Insecticides May Up Autoimmune Disease Risk: Women who are exposed to insecticides at home or in the workplace have an increased risk of rheumatoid arthritis, or systemic lupus erythematosus, according to a study published in the February issue of Arthritis Care & Research.
Drug targets Lupus by tricking Immune System: Now two companies are working together to attack the disease with an experimental drug that tricks the immune system into behaving more normally.
New Research Uncovers Why Many With Lupus Are Resistant to Treatments: New Research Uncovers Why Many With Lupus Are Resistant to Traditional Treatments, Findings Could Lead to Lower Doses of Medication for Lupus Patients, Reducing Serious Side Effects.
Pfizer, deCode Genetics Strike Deal To Look For New Lupus Drug Targets
ImmuPharma chief confident and upbeat on the prospects for Lupuzor
New drug target for immune diseases discovered: Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis. The research is published online in the September issue of Nature Immunology.
Urine Protein Test Might Help Diagnose Kidney Damage from Lupus: Simple urine tests for four proteins might be able to detect early kidney disease in people with lupus, researchers at UT Southwestern Medical Center have found in an animal study.
Lupus not identical in twins: Lupus can tell identical twins apart by the distinguishing marks the pairs carry on their DNA.
FDA Priority Review Designation for BENLYSTA®: Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA® (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
Black Women With SLE Develop Cardiovascular Disease At Early Age: A recent study by researchers at Penn State College of Medicine found significant racial disparities in the age of systemic lupus erythematosus (SLE) patients at the time of hospital admission for cardiovascular disease (CVD) events and CVD-related death.
Vitamin D Found to Influence Over 200 Genes: Vitamin D Found to Influence Over 200 Genes, highlighting links to disease. The extent to which vitamin D deficiency may increase susceptibility to a wide range of diseases is dramatically highlighted in newly published research. Scientists have mapped the points at which vitamin D interacts with our DNA -- and identified over two hundred genes that it directly influences.
Overactive Blood Platelets May Play Role in Lupus: Overactive blood platelets could trigger inflammation in those with lupus, but the anti-clotting drug Plavix might ease the painful symptoms of this autoimmune disease, a new study suggests.
Molecular Gatekeeper Of Arthritis Identified: Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report in a study published in The Journal of Experimental Medicine.
National Pharmaceuticals Lead Therapeutic Drug, GLB333 for Lupus
Abatacept Found Ineffective In Treatment Of Non-Life Threatening Lupus: Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE).
Discovery of a Cell that Suppresses the Immune System: In autoimmune diseases such as lupus, some of these antibodies, called autoantibodies, react against the individual's own tissues. A newly defined subset of T cells, called CD8 Treg, inhibits production of these autoantibodies.
Epratuzumab,Enters Phase III Trials After Promising Results: For the past 50 years there have been no new drug treatments approved for systemic lupus erythamatosus (SLE). Now, at last, that situation could soon change. The FDA is currently reviewing one new drug whilst another, epratuzumab, in development by Immunomedics Inc and UCB, is about to start phase III clinical trials after showing promising results in a smaller trial. If successful, it could be available within a few years.
New clinical test to predict lupus flares moves closer to the market: Lupus Research Institute investigator's innovative discovery of a simple blood test for lupus flares now licensed for development A discovery made by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at the University of Minnesota has been licensed to a major clinical laboratory for development and could soon result in a test that quickly and easily enables patients and their physicians to determine when a lupus flare is imminent.
Hospital for Special Surgery scientists share advances in lupus
Lupus Linked to Increased Risk of Cancer: Higher Lymphoma Rates Among Systemic Lupus Patients Appears to Drive Trend
Statins Not Routinely Indicated For Children & Adolescents With Lupus: While statins are known to help prevent the progression of atherosclerosis, research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta indicates they should not be routinely prescribed in children and adolescents with lupus despite their increased risk of premature atherosclerosis
Researchers Find Clue to Heart Complications in Neonatal Lupus: Women with anti-SSA/Ro antibodies and a previous child who has heart block—a condition where the electrical signal that makes the heart beat is damaged—may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil®), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
UCB lupus candidate shows disease benefits: A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer UCB says.
ACR: Lupus Patients Need Lipid Screening: Patients with systemic lupus erythematosus -- and particularly women -- are not routinely being screened for lipids, despite their widely recognized risk for cardiovascular disease, a researcher said here.
F.D.A. Panel Backs Drug for Lupus: What could become the first new drug approved to treat lupus in more than half a century moved a big step closer to the market on Tuesday by winning an endorsement from a federal advisory committee.
FDA Extension Of Benlysta® PDUFA Target Date To 10th March 2011: GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from 9th December 2010 to 10th March 2011.
Argos Therapeutics Initiates Dosing In Phase 1 Clinical Trials: Argos Therapeutics announced that it has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (SLE). AGS-009 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with the ability to bind and neutralize human interferon alpha (IFN-alpha).
Children With Lupus Have More Lethal Form Of Kidney Disease: Kidney disease caused by the autoimmune disease lupus may be twice as lethal in children as kidney disease caused by other disorders, according to research led by Johns Hopkins Children's Center investigators.
Unexpected Role In Lupus Played By Immune Cell: A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE).
Lupus Treatment May Soon Take Leap Forward: For years now, doctors have made slow, incremental progress in the treatment of lupus, a chronic autoimmune condition that can wrack the body and seriously affect a person's health.
Low Vitamin D levels can cause autoimmune lung disease--study: As per a novel study led by Brent Kinder, MD, UC Health pulmonologist, director of the Interstitial Lung Disease Center at the University of Cincinnati, Vitamin D deficiency can lead to a higher risk of developing autoimmune lung diseases
Yale Researchers Find A Surprising Culprit in Lupus: Yale University researchers were able to reduce symptoms of lupus in mice by eliminating a key immune system cell and in doing so may have identified a new therapeutic target for a variety of other autoimmune diseases.
Link To Increased Atherosclerosis Risk In Lupus Patients: Researchers in China have demonstrated interferon-alpha (IFN-a) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE).
Lupus breakthrough offers hope in the future for those with disease: A massive lupus study led by Oklahoma Medical Research Foundation researchers has developed its first major breakthrough, throwing the veil off a gene that affects the complex autoimmune disease that causes the body to attack itself. Read more: http://newsok.com/lupus-breakthrough-offers-hope-in-the-future-for-those-with-disease/article/3531580#ixzz1BQs15cyC
Women with Lupus Need Better Preventive Health Services
Umbilical cord blood-derived stem cells studied for lupus therapy
Hydroxychloroquine Scores Big in Lupus: The past 12 months have brought a slew of studies making a persuasive case for hydroxychloroquine as a far more important drug in lupus than previously thought. Indeed, the drug could now even be considered essential.
Scientists identify regulatory defect that drives lupus: A group of scientists have identified a regulatory defect that drives lupus.
Slow-to-Heal Wounds Linked to Autoimmune Diseases: Nearly 6.5 million Americans have wounds that take months or even years to heal. Many of these wounds are a consequence of diabetes, which damages blood vessels and interferes with normal skin repair.
Research uncovers key to understanding cause of lupus: Potentially impacting future diagnosis and treatment of lupus, an immune illness affecting more than 5 million people worldwide, researchers at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech have likely uncovered where the breakdown in the body's lymphocyte molecular regulatory machinery is occurring.
New lupus clue: Failed autoimmune suppression mechanism: Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.
Autoantibodies predate the onset of Systemic Lupus Erythematosus: Introduction Autoantibodies have a central role in systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been reported both in patients with SLE and those with rheumatoid arthritis, suggesting a gradual development of these diseases.
Earlier Rituximab Better for Lupus Nephritis Patients
Benlysta For Lupus Likely To Be Approved This Thursday: Benlysta (belimumab) is expected to gain US approval this week by the Food and Drug Administration (FDA), USA, for the treatment of lupus (systemic lupus erythematosus).
FDA approves Benlysta to treat Lupus: FDA approves Benlysta to treat lupus First new lupus drug approved in 56 years
Autoimmune Diseases and Taste: Scientists supported by the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, will be presenting their latest research findings at the 2011 Annual Meeting of the Association for Chemoreception Sciences (AChemS).
New Therapies for AutoImmune Diseases
Dynavax to get $6 million payment from Glaxo for new lupus drug
Dynavax initiates first human trial in lupus programme: Dynavax Technologies Corporation announced the start of dosing in the first human clinical trial in its lupus programme. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK), its partner in a worldwide strategic alliance. GSK has an exclusive
Changes In Incidence Of End-Stage Renal Disease: New research documenting changes in the incidence and outcomes of end-stage renal disease (ESRD) in the U.S. between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans.
Novel Pathophysiologic Mechanism Responsible For Autoimmunity
FDA Approves New Discount Prescriptions for Lupus: The FDA has announced the approval of Benlysta, promising discount prescriptions for the treatment of Lupus.
GlaxoSmithKline & HGS, Receive Positive Opinion In Europe for Benlysta: GlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For Benlysta®
African-Americans With SLE More Responsive To Flu Vaccine: African-Americans With SLE More Responsive To Flu Vaccine Than Patients Of European Descent
GSK Lupus Treatment Benlysta Reaches Europe After US Approval: The first treatment developed for lupus in over 50 years has been recommended for approval by the European Union this week.
Lupus has negative impact on patients’ careers: LUPUS EUROPE (LE) and UCB today announced results from the pan-European Lupus European Online (LEO) survey, believed to be the first online survey of its kind completed by lupus patients using validated measures assessing the impact of lupus.
Vidofludimus Superior To Cyclophosphamide And MMF: 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus (SLE) at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.
Novel Drug Candidate May Block Lupus’ Attack on the Brain: Some ten years ago, scientist Dr. Betty Diamond came to the Lupus Research Institute with a critical clinical question that could only be answered with molecular research – why do four out of five people with lupus suffer with some type of neuropsychiatric difficulty? With funding granted on the mer
SuppreMol Employs Protagen Biomarkers In SLE Study: SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, recently announced a collaboration ...
Vitamin D Deficiency Among Systemic Lupus Erythematosis Patients: Researchers have just found that vitamin D levels among systemic lupus erythematosis (SLE) patients directly relates to the severity of the disease and the development of the infection.
Autoimmune diseases may be caused by newly discovered cell: “Not only do these cells appear more frequently in females, their activation depends on a gene of which women have two copies and men only one.”
Benlysta is Heading in the Right Direction: Benlysta is Heading in the Right Direction, but Uptake is Somewhat Slower Than Originally Anticipated According to a New Report by BioTrends Research Group
Newly Discovered B Cells may finally give some answers: Researchers at National Jewish Health have discovered a type of cell that may contribute to autoimmune disease. The findings also suggest why diseases such as lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently than men.
Response to Flu Vaccine Varies in Lupus: Race and the presence of hematologic abnormalities were among the factors influencing response to influenza vaccine among patients with systemic lupus erythematosus, a prospective study found.
BRM gets grant for lupus research: Biomedical Research Models Inc. will share a $571,610 federal grant with a New York medical research organization for work on a treatment for lupus.
Defective gene behind arthritis, diabetes: Study: Scientists at Mount Sinai Hospital identified a defective gene which can spur the development of rheumatoid arthritis, diabetes, lupus and other autoimmune diseases.
New Hope for Treatment of Lupus on the Rise: With a patient's own adult stem cells, there is new hope for the intractable autoimmune disease lupus - systemic lupus erythematosus (SLE) - which is difficult to cure.
Continued Treatment For Lupus May Boost Survival of Patients: Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease—a finding that could reverse long-standing clinical practice.
Funding Aims to Improve Lupus Detection Nationwide: The Lupus Alliance of America, a member of the Lupus National Coalition, joins the S.L.E. Lupus Foundation and Lupus Research Institute (LRI) in commending the entire U.S. Senate Appropriations Committee for recognizing the urgent need for greater health education in lupus
Lupus Drug Rejected By U.K. Health Services: The lupus drug Benlysta has been rejected by the U.K.'s National Institute for Health and Clinical Excellence, which claims that it should not be made available on the National Health Service.
Two Studies Show Potential for Novel Biomarkers: Two Studies Show Potential for Novel Biomarkers to Replace Surgical Biopsy in Detecting and Monitoring Lupus Kidney Disease.
Statin Therapy Ineffective for Lupus: Women with lupus are 50 times more likely to have a heart attack; and all lupus patients are eight times more likely to develop premature coronary heart disease than the general population.
Lupus Classification System Too Complicated: A simpler system would make it easier for clinicians to treat kidney problems in lupus patients.
XToll Completely Prevented Cutaneous Lupus In Animal Study: CBio Limited have announced the publication of their animal trial on the advanced access site of the Oxford Journals publication, Nephrology Dialysis Transplantation.
Steroid Medications Tied to Vitamin D Deficiency: People who use oral steroid medications may be at greater-than-average risk of a serious vitamin D deficiency, a new study suggests.
Partners line up for a piece of ImmuPharma's lupus drug: Shares in ImmuPharma have leapt almost 25% on the news that the UK firm's lupus treatment Lupuzor, recently returned Cephalon, has been granted approval to start Phase III studies and received fast-track designation from regulators in the USA.
Vitamin D, Interferon Alpha Vaccine Show Promise Against Lupus: Two experimental treatments take aim at the destructive immune response believed to cause lupus, according to new research presented at the American College of Rheumatology annual meeting.
FDA Grants Lupuzor Fast Track Status: ImmuPharma plc, the specialist discovery and development pharmaceutical company has provided an update on the development status of its Lupus drug candidate Lupuzor.
ACR: Antimalarial Drug Protects Kidneys in Lupus: Treatment with hydroxychloroquine among patients with systemic lupus erythematosus was significantly protective against the development of renal failure, a researcher reported here.
Human Genome, GlaxoSmithKline Initiate New Phase 3 Trial Of Lupus Drug: Human Genome Sciences, Inc. (HGSI: News ) and GlaxoSmithKline Plc (GSK: News ,GSK.L: News ) Thursday announced that they have initiated a new Phase 3 trial to evaluate the efficacy, safety and tolerability of Benlysta, or belimumab, in autoantibody-positive adults with active systemic lupus erythema
Benlysta™ Trial Results in an Historic Research Breakthrough: Second successful phase III trial points to the first new lupus treatment in over 50 years. The Lupus Alliance of America, as a member of the Lupus National Coalition, are thrilled to make this announcement and to be a part of this history making drug!
Major Report to Congress by Secretary of Health and Human Services: New report resulting from Lupus Research Institute’s congressional advocacy describes state of lupus research, impact of disease, and barriers to care
HGS and Lonza announce manufacturing agreeement for Benlysta.: Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA(R), A Potential New Treatment For Systemic Lupus Erythematosus
LRI Underscores Urgent Need for Research in Pediatric SLE: The Lupus Research Institute (LRI) National Coalition of state and local lupus groups, alarmed at the crucial need for answers to the devastating effects of lupus when diagnosed in the young, is sponsoring key programming in lupus pediatrics at the International Lupus Congress in Vancouver, Canada from June 24 to 27.
UCLA study identifies genetic variation linked to lupus in Asian men: Genes reside along long chains of DNA called chromosomes. UCLA researchers have found that a variation in a gene on the sex chromosome X may enhance an immune response that leads to lupus in men.
LRI releases results from scientific research impact report on lupus
FDA Meeting Agenda for Benlysta Approval Hearings
The Lupus Drug Gold Mine: Lupus has puzzled doctors since it was identified in the 1800s. For unknown reasons, the body makes antibodies against itself.
HGS and GlaxoSmithKline Report Topline Results on Benlysta: Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).
Important Control Mechanism Behind Autoimmune Diseases Discovered: Researchers at Karolinska Institutet have discovered a new control mechanism in our immune system. The discovery is of potential significance to the treatment of serious diseases such as MS (multiple sclerosis), rheumatoid arthritis, and SLE (systemic lupus erythematosus).
Mouse Model Demonstrates The Immune Cell's Role In Lupus Nephritis: National Institutes of Health scientists have discovered that the activation of immune cells called basophils causes kidney damage in a mouse model of lupus nephritis.
Twin Epigenetics Study IDs Methylation Differences in Lupus: NEW YORK (GenomeWeb News) – Epigenetic changes, specifically differences in DNA methylation, may contribute to environmental factors involved in systemic lupus erythematosus risk, according to an online study in Genome Research today.
Immune Responses to Flu Vaccine Are Diminished in Lupus Patients: Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs.
Vitamin D Tests May Reveal Risk for Lupus: Lupus, the autoimmune disorder which recently received a media spotlight in the wake of Michael Jackson's death, may be catalyzed by low levels of vitamin D in people susceptible to the disease, according to new research.
Benlysta Effective in Some Lupus Sufferers: The experimental lupus drug Benlysta has defied skeptics by significantly improving the symptoms of this difficult-to-treat disease in a late stage trial, announced Human Genome Sciences (HGSI) and partner GlaxoSmithKline (GSK) on Monday.
Good News for Lupus at the American College of Rheumatology Meeting: Drug company Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today reported details of the first of their two crucial Phase 3 trials of belimumab (Benlysta™) in people with systemic lupus erythematosus at the American College of Rheumatology’s (ACR) annual scientific meeting in Philadelphia.
Cellular Mechanism That Causes Lupuslike Symptoms In Mice Identified: Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.
Lupus Patients Perceive Benefit From Cardiovascular Disease Prevention: According to a new study by Hospital for Special Surgery investigators presented at the American College of Rheumatology meeting on October 21 in Philadelphia, most lupus patients are not aware that their condition puts them at a higher risk for cardiovascular disease and a counseling program is a valuable way to promote education and lifestyle change.
Antibody Puts Young Women at Risk of Stroke, MI: Women with the lupus anticoagulant -- an antiphospholipid antibody -- had five times the risk of heart attack of other women, and a 40-fold greater risk of stroke, researchers said.
Uncovering the Mysteries of Immunity, and of Lupus: Scientists are seeking to uncover why the immune system attacks healthy cells in lupus. Antinuclear antibodies, like those shown here in lupus-prone mice, are a hallmark of the disease.
Roche suspends arthritis drug study after deaths: US biotechnology company Biogen Idec and Swiss drugmaker Roche Holding are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug's future.
Testing For Urinary Proteins Might Help Diagnose Kidney Damage From Lu: Simple urine tests for four proteins might be able to detect early kidney disease in people with lupus, researchers at UT Southwestern Medical Center have found in an animal study.
ACR Partners with HHS for Lupus Initiative: The American College of Rheumatology has announced that it will work in conjunction with the US Department of Health and Human Services' Offices of Minority Health, Women's Health, and the Surgeon General to launch "Eliminating Health Disparities in Lupus" (EHDL), an educational initiative aimed at eliminating ethnic and racial disparities in the diagnosis and treatment of lupus.
Rescue NET For Lupus Patients: Scientists at the Max Planck Institute for Infection Biology in Berlin together with medical scientists from the University of Erlangen succeeded in elucidating basic principles of the disease.